Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Research

Ankasa Regenerative Therapeutics

Ankasa Regenerative Therapeutics' headquarters in South San Francisco, CA, United States

Sanford J. Madigan

Description

People

Jobs